Summary:
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, dose-ranging,
international, multicenter, 12-week study. It is designed to assess the therapeutic dose, efficacy,
and safety of treatment with SAR441566 in male and female adults with moderate to severe
plaque psoriasis.
Qualified Participants Must:
• Be 18-75 years old
•
Have a diagnosis of plaque psoriasis for at least 6 months
Qualified Participants May Receive:
Up to $700
Free study-related medication